Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)

This study has been completed.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: June 28, 2012
Last updated: April 5, 2016
Last verified: April 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2016
  Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)